Literature DB >> 9532637

Increased eotaxin-mRNA expression in non-atopic and atopic nasal polyps: comparison to RANTES and MCP-3 expression.

J Bartels1, S Maune, J E Meyer, R Kulke, C Schlüter, J Röwert, E Christophers, J M Schröder.   

Abstract

Eosinophilic tissue infiltration of nasal mucosa typical for allergic rhinitis and chronic polypous sinusitis may be due to chemotactic activity of chemokines specific for eosinophils. The CC-chemokines eotaxin, RANTES and MCP-3 have been postulated to be involved in the recruitment of eosinophils to certain inflamed tissues. To explore their possible role in chronic polypous sinusitis we examined eotaxin-, RANTES- and MCP-3-gene expression in human nasal polyps and normal human nasal mucosa of patients undergoing endonasal surgery for treatment of chronic polypous sinusitis. Using gene-specific primers in semi-quantitative reverse-transcriptase polymerase-chain-reaction experiments we found elevated expression of eotaxin- and RANTES-mRNA but no MCP-3-mRNA in non-atopic and atopic nasal polyps when compared to normal nasal mucosa.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9532637

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  13 in total

1.  Plasma RANTES and eotaxin levels are correlated with the severity of chronic rhinosinusitis.

Authors:  Pin-Zhir Chao; Chi-Ming Chou; Chen-Ho Chen
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-01-24       Impact factor: 2.503

Review 2.  [Strategies of the nasal mucous membranes for defense against infection. Current knowledge of antimicrobial peptides].

Authors:  S Maune
Journal:  HNO       Date:  2005-05       Impact factor: 1.284

Review 3.  The role of local steroid injection for nasal polyposis.

Authors:  Marcelo B Antunes; Samuel S Becker
Journal:  Curr Allergy Asthma Rep       Date:  2010-05       Impact factor: 4.806

4.  15-Lipoxygenase 1 in nasal polyps promotes CCL26/eotaxin 3 expression through extracellular signal-regulated kinase activation.

Authors:  Zhipeng Li; Ming Zeng; Yanhan Deng; Jinming Zhao; Xiuxia Zhou; John B Trudeau; Ezequiel Goldschmidt; John A Moore; Hongwei Chu; Weitian Zhang; Shankai Yin; Zheng Liu; Y Peter Di; Stella E Lee; Sally E Wenzel
Journal:  J Allergy Clin Immunol       Date:  2019-07-11       Impact factor: 10.793

5.  Fundamental signals that regulate eosinophil homing to the gastrointestinal tract.

Authors:  A Mishra; S P Hogan; J J Lee; P S Foster; M E Rothenberg
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

Review 6.  Pharmacological management of nasal polyposis.

Authors:  Claus Bachert; Jean-Baptiste Watelet; Philippe Gevaert; Paul Van Cauwenberge
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Pathogenesis of nasal polyposis.

Authors:  K E Hulse; W W Stevens; B K Tan; R P Schleimer
Journal:  Clin Exp Allergy       Date:  2015-02       Impact factor: 5.018

Review 8.  Mediators in nasal polyposis.

Authors:  Claus Bachert; Philippe Gevaert; Gabriele Holtappels; Paul van Cauwenberge
Journal:  Curr Allergy Asthma Rep       Date:  2002-11       Impact factor: 4.806

9.  Significance of susceptible gene expression profiles in nasal polyposis.

Authors:  De Yun Wang
Journal:  Clin Exp Otorhinolaryngol       Date:  2008-12-26       Impact factor: 3.372

Review 10.  Superantigens and nasal polyps.

Authors:  Claus Bachert; Thibaut van Zele; Philippe Gevaert; Lore De Schrijver; Paul Van Cauwenberge
Journal:  Curr Allergy Asthma Rep       Date:  2003-11       Impact factor: 4.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.